{"type":"trials","record":{"id":29062,"source_id":"clinicaltrials-gov","external_id":"NCT04733534","title":"An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer","brief_summary":"This is a first-in survivor pilot study with the goal of establishing preliminary evidence of efficacy, safety, and tolerability of two senolytic regimens to reduce markers of cellular senescence (primary outcome: p16\\^INK4a) and improve frailty (primary outcome: walking speed) in adult survivors of childhood cancer. If successful, this pilot would provide the preliminary evidence needed for a phase 2, randomized, placebo-controlled trial to establish efficacy. Primary Objective * The primary aim of this proposal is to test the efficacy of two, short duration senolytic regimens: 1) combination of Dasatinib plus Quercetin and 2) Fisetin alone, to improve walking speed and decrease senescent cell abundance in blood (p16\\^INKA): * Primary endpoints of this trial will be change in walking speed and senescent cell abundance in blood (p16\\^INK4A) determined at baseline and again at 60 days, within an individual arm. Extended follow up at 150 days will assess the permanence of change after completion of the trial. Secondary endpoints of this trial will be effect of intervention on additional measures of frailty (beyond walking speed; Fried criteria) and on other cell senescence markers, markers of inflammation, insulin resistance, bone resorption, and cognitive function. Secondary Objectives The secondary aim is to test the safety and tolerability of two different senolytic therapies. Exploratory Objectives * To compare the efficacy of the two senolytic regimens in improving walking speed and decreasing senescent cell abundance * To evaluate the longitudinal pattern in measures of frailty.","overall_status":"Active Not Recruiting","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"St. Jude Children's Research Hospital","enrollment":110,"countries":["United States"],"start_date":"2022-06-06","completion_date":"2027-12-01","last_update_date":"2026-04-24","source_url":"https://clinicaltrials.gov/study/NCT04733534","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:16:08.862442+00:00","last_seen_at":"2026-09-25T06:10:07.378+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"18 Years","comparator":"Dasatinib plus Quercetin; Fisetin","organization":"St. Jude Children's Research Hospital","interventions":["Dasatinib plus Quercetin","Fisetin"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Change in walking speed — Baseline","Change in Walking Speed — Day 30","Change in Walking Speed — Day 60","Change in Walking Speed — Day 150","Senescent cell abundance in blood (p16INK4A) — Baseline","Senescent cell abundance in blood (p16INK4A) — Day 7","Senescent cell abundance in blood (p16INK4A) — Day 30","Senescent cell abundance in blood (p16INK4A) — Day 60","Senescent cell abundance in blood (p16INK4A) — Day 150","Safety of two different senolytic therapies as assessed by treatment-related adverse events using CTCAE v5.0 — 150 days","Tolerability of two different senolytic therapies as assessed by treatment-related adverse events using CTCAE v5.0 — 15…"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","source_has_results":false},"controlled_terms":["Frailty","Childhood Cancer","Dasatinib plus Quercetin","Fisetin"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: frailty.","quality_checked_at":"2026-09-25T06:10:20.034853+00:00","duplicate_cluster_key":"id:nct04733534","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2022-06-06 to 2027-12-01","comparator":"Dasatinib plus Quercetin; Fisetin","confidence":"structured-source","population":"ALL · 18 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:10:07.442Z","intervention":["Dasatinib plus Quercetin","Fisetin"],"participants":110,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change in walking speed — Baseline","Change in Walking Speed — Day 30","Change in Walking Speed — Day 60","Change in Walking Speed — Day 150","Senescent cell abundance in blood (p16INK4A) — Baseline","Senescent cell abundance in blood (p16INK4A) — Day 7","Senescent cell abundance in blood (p16INK4A) — Day 30","Senescent cell abundance in blood (p16INK4A) — Day 60","Senescent cell abundance in blood (p16INK4A) — Day 150","Safety of two different senolytic therapies as assessed by treatment-related adverse events using CTCAE v5.0 — 150 days","Tolerability of two different senolytic therapies as assessed by treatment-related adverse events using CTCAE v5.0 — 15…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"frailty","is_published":true,"match_reasons":["Title contains controlled term: frailty.","Abstract contains controlled term: frailty.","Source terminology contains: frailty.","Title supplies longevity context: senescence, frailty.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Frailty","slug":"frailty"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/29062","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}